FibroGen hopes to buck its pamrevlumab trend
Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.
Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.
